Q1 2020

Filed May 7, 2020 · 10-Q · 37 days after period end · 0001564590-20-022971

Q1 2020 · 10-Q

Revenue

$379.00K

±0.0% vs Q1 2019

Net Income

-$15.24M

N/M vs Q1 2019

EPS Diluted

-$0.56

N/M vs Q1 2019

Operating Income-$15,100,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2020	Q1 2019	Q1 2018	Q1 2017
Revenue	$379.00K	$379.00K	$379.00K	$305.00K
Net Income	-$15.24M	-$14.30M	-$19.40M	-$12.97M
EPS Diluted	-$0.56	-$0.53	$0.79	-$2.85

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR